ReWalk Exoskeleton Shows Long-Term Home Use Viability in New Study
Event summary
- ReWalk Personal Exoskeleton used for a median of 33 months in a peer-reviewed study, with no reported falls or fractures.
- Participants averaged over 3,000 steps per month, demonstrating sustained real-world utilization.
- High user satisfaction reported, with median QUEST satisfaction score of 4.2 out of 5.
- Study published in Spinal Cord Series and Cases, an official journal of the International Spinal Cord Society.
The big picture
The study provides critical long-term evidence for ReWalk's safety and efficacy, addressing a gap in existing literature focused on shorter-term, controlled settings. This data could bolster Lifeward's efforts to expand access and reimbursement, positioning ReWalk as a sustainable solution for chronic paraplegia management. The findings also underscore the importance of caregiver availability, a factor that could influence future product design and support services.
What we're watching
- Reimbursement Expansion
- Whether the long-term evidence will accelerate Medicare and private payer coverage for ReWalk.
- Market Adoption
- The pace at which clinical and real-world evidence translates into broader adoption by patients with chronic paraplegia.
- Competitive Positioning
- How Lifeward leverages this data to differentiate ReWalk in the growing exoskeleton market.
Related topics
